[Helicobacter pylori eradication therapy does not prevent gastric cancer development in all patients].

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Author(s): Take S;Take S; Ishiki K; Mizuno M
  • Source:
    Gan to kagaku ryoho. Cancer & chemotherapy [Gan To Kagaku Ryoho] 2011 Mar; Vol. 38 (3), pp. 353-7.
  • Publication Type:
    Journal Article
  • Language:
    Japanese
  • Additional Information
    • Source:
      Publisher: Gan To Kagaku Ryohosha Country of Publication: Japan NLM ID: 7810034 Publication Model: Print Cited Medium: Print ISSN: 0385-0684 (Print) Linking ISSN: 03850684 NLM ISO Abbreviation: Gan To Kagaku Ryoho Subsets: MEDLINE
    • Publication Information:
      Publication: Tokyo : Gan To Kagaku Ryohosha
      Original Publication: Tōkyō, Gan to Kagaku Ryōhōsha [1974?]-
    • Subject Terms:
      Helicobacter pylori*; Helicobacter Infections/*therapy ; Stomach Neoplasms/*prevention & control; Follow-Up Studies ; Gastroscopy ; Helicobacter Infections/microbiology ; Humans ; Stomach Neoplasms/microbiology
    • Abstract:
      We previously reported that eradication of Helicobacter pylori reduced the risk of gastric cancer developing in patients with peptic ulcer diseases. In the present study, we followed up with our patient group to investigate the occurrences and clinical features of gastric cancers that developed after cure of the infection. Prospective post-eradication evaluations were conducted on 1, 674 consecutive patients who had received successful H. pylori eradication therapy. The patients underwent endoscopic examination before eradication therapy to test for peptic ulcers, background gastric mucosal atrophy, and H. pylori infection. After confirmation of the cure of infection, the annual follow-up endoscopy was performed. The patients were followed up to more than 10 years. During the follow-up, their risk of developing gastric cancer after the cure of infection was almost the same as we reported previously. There was still a risk of developing gastric cancer of both the intestinal and diffuse types. The grade of gastric mucosal atrophy present before receiving eradication therapy was closely related to the development of gastric cancer after eradication of H. pylori. The stage of most gastric cancer was at the early TNM stage, but advanced cancer was observed in patients who skipped regular endoscopic surveillance. H. pylori eradication therapy does not prevent gastric cancer development in all infected patients. Thus, it is important to inform patients about the risk of gastric cancer after eradication therapy and to offer them surveillance endoscopy.
    • Publication Date:
      Date Created: 20110316 Date Completed: 20110421 Latest Revision: 20201209
    • Publication Date:
      20231215
    • Accession Number:
      21403436